OCS

Oculis Holding AG · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website oculis.com
Employees(FY) 28
ISIN nan

Performance

+2.38%

+13.05%

+42.33%

+44.51%

+51.2%

YTD

+57.22%

Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Advanced Technical Analysis

Technical Analysis of OCS 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 68 further supports this positive outlook. However, the Oscillators Score of 46 suggests a neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should monit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of OCS

Stock Rank

Recent News & Updates

2024-12-06 16:00
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities(GlobeNewswire)
2024-12-06 03:00
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities(Globenewswire)
2024-11-29 04:00
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated(GlobeNewswire)
2024-11-28 15:00
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated(Globenewswire)
2024-11-27 04:15
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities(GlobeNewswire)
2024-11-26 15:15
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities(Globenewswire)
2024-11-13 04:00
Oculis to Present at the Stifel 2024 Healthcare Conference(GlobeNewswire)
2024-11-13 04:00
Oculis to Present at the Stifel 2024 Healthcare Conference(GlobeNewswire)
2024-11-12 15:00
Oculis to Present at the Stifel 2024 Healthcare Conference(Globenewswire)
2024-11-08 05:09
Oculis Holding Third Quarter 2024 Earnings: Misses Expectations(Simply Wall St.)
2024-11-07 04:00
Oculis Reports Q3 2024 Financial Results and Provides Company Updates(GlobeNewswire)
2024-11-06 15:00
Oculis Reports Q3 2024 Financial Results and Provides Company Updates(Globenewswire)
2024-10-30 11:12
Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39%(Simply Wall St.)
2024-10-21 13:04
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees(GlobeNewswire)
2024-10-21 04:00
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees(GlobeNewswire)
2024-10-21 01:04
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees(Globenewswire)
2024-10-20 16:00
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees(Globenewswire)
2024-10-15 04:00
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024(GlobeNewswire)
2024-10-14 16:00
Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024(Globenewswire)
2024-10-02 04:00
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer(GlobeNewswire)
2024-10-01 16:00
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer(Globenewswire)
2024-09-19 13:00
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award(GlobeNewswire)
2024-09-19 01:00
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award(Globenewswire)
2024-08-30 06:40
Oculis Holding (NASDAQ:OCS) Is In A Good Position To Deliver On Growth Plans(Simply Wall St.)
2024-08-29 04:00
Oculis to Present at Upcoming September Investor Conferences(GlobeNewswire)
2024-08-28 16:00
Oculis to Present at Upcoming September Investor Conferences(Globenewswire)
2024-08-27 16:00
Oculis Publishes Consolidated Q2 Financial Statements and MD&A(GlobeNewswire)
2024-08-27 04:00
Oculis Publishes Consolidated Q2 Financial Statements and MD&A(Globenewswire)
2024-08-27 04:00
Oculis Reports Q2 Financial Results and Provides Recent Company Update(GlobeNewswire)
2024-08-27 04:00
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update(GlobeNewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.